Keros Therapeutics, Inc. (KROS) DCF Valuation

Keros Therapeutics, Inc. (KROS) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

Keros Therapeutics, Inc. (KROS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Streamline your analysis and improve precision with our [KROS] DCF Calculator! Utilizing real data from Keros Therapeutics, Inc. and customizable assumptions, this tool empowers you to forecast, analyze, and value Keros Therapeutics like an expert investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 10.0 .0 20.1 .0 .2 .1 .0 .0 .0 .0
Revenue Growth, % 0 -100 0 -100 0 -50 -50 -50 -50 -50
EBITDA -11.9 -44.9 -56.4 -103.1 -152.2 .0 .0 .0 .0 .0
EBITDA, % -118.9 100 -280.46 100 -100779.47 -20 -20 -20 -20 -20
Depreciation .4 .6 .9 1.6 .8 .0 .0 .0 .0 .0
Depreciation, % 4.38 100 4.47 100 539.74 61.77 61.77 61.77 61.77 61.77
EBIT -12.3 -45.5 -57.3 -104.7 -153.0 .0 .0 .0 .0 .0
EBIT, % -123.28 100 -284.93 100 -101319.21 -20 -20 -20 -20 -20
Total Cash 7.0 265.9 230.0 279.0 331.1 .1 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .2 .0 .0 .0 .0 .0
Account Receivables .9 .2 18.0 .8 1.1
Account Receivables, % 9.22 100 89.55 100 722.52
Inventories .8 1.5 3.1 -.8 .0 .0 .0 .0 .0 .0
Inventories, % 7.59 100 15.21 100 0 44.56 44.56 44.56 44.56 44.56
Accounts Payable 2.1 2.1 3.6 3.3 5.5 .1 .0 .0 .0 .0
Accounts Payable, % 20.88 100 18.13 100 3609.27 67.8 67.8 67.8 67.8 67.8
Capital Expenditure -.3 -.3 -1.0 -1.2 -2.5 .0 .0 .0 .0 .0
Capital Expenditure, % -2.71 100 -5.09 100 -1631.79 -21.56 -21.56 -21.56 -21.56 -21.56
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -12.3 -45.4 -59.3 -104.7 -153.0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -11.8 -45.0 -77.3 -83.6 -153.6 -4.4 .0 .0 .0 .0
WACC, % 10.11 10.11 10.11 10.11 10.11 10.11 10.11 10.11 10.11 10.11
PV UFCF
SUM PV UFCF -3.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -4
Net Debt -317
Equity Value 313
Diluted Shares Outstanding, MM 29
Equity Value Per Share 10.62

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real KROS financials.
  • Real-World Data: Historical data and forward-looking estimates (highlighted in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the effect of your inputs on Keros Therapeutics’ valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • 🔍 Real-Life KROS Financials: Pre-filled historical and projected data for Keros Therapeutics, Inc. (KROS).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Keros Therapeutics’ intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Keros Therapeutics’ valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • Step 1: Download the prebuilt Excel template with Keros Therapeutics' (KROS) data included.
  • Step 2: Explore the pre-filled sheets and familiarize yourself with the key metrics.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Keros Therapeutics' intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose Keros Therapeutics, Inc. (KROS)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Commitment to Quality: Rigorous research and development processes ensure high standards.
  • Collaborative Approach: Partnerships with leading organizations to enhance treatment options.
  • Patient-Centric Focus: Our mission is to improve the lives of patients through targeted therapies.
  • Proven Expertise: A team of experienced professionals dedicated to advancing healthcare.

Who Should Use This Product?

  • Investors: Evaluate Keros Therapeutics’ valuation before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess future projections.
  • Startup Founders: Understand how biotech firms like Keros Therapeutics are appraised.
  • Consultants: Provide detailed valuation analyses for client projects.
  • Students and Educators: Utilize real-world examples to study and teach valuation strategies.

What the Template Contains

  • Historical Data: Includes Keros Therapeutics' past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Keros Therapeutics' intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Keros Therapeutics' financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.